Zelboraf

FDA approves new melanoma drug

The U.S. Food and Drug Administration (FDA) has approved Zelboraf (vemurafenib) for use in patients with metastatic or unresectable melanoma who have the BRAF V600E mutation. Read more.

Reader Survey

Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.

Survey

Test Your Knowledge

Emotional Intel TYK

In what way does emotional intelligence affect nursing leaders in team and patient care settings?

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • This field is hidden when viewing the form

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.